OKYO

SEC filing OKYO Appoints Marta Sacchetti, MD, PhD to Scientific Advisory Board, Advances Urcosimod for Neuropathic Corneal Pain Treatment

14d ago

SEC filing OKYO Reports Upcoming CEO Presentation at Eyecelerator May 1 2026, CSO to Present at ARVO May 5 2026, Urcosimod Phase 2 Success, Fast Track Designation, 18-Patient NCP Trial Shows Pain Reduction, Phase 2b/3 Study Planned 2026

34d ago

SEC filing OKYO Pharma Announces Non-Executive Director Acquires 5,000 Shares at $1.61, Total Holding 31,201

75d ago

SEC filing OKYO Pharma Announces CDO Jacob Acquires 30,980 Shares at $1.59, Total Holding 108,920

75d ago

SEC filing OKYO Pharma LTD Reports $0 Revenue, $0 EPS, No Deals, 0% Growth

82d ago

SEC filing OKYO Prices $20M Public Offering, 10.8M Shares at $1.85

109d ago

News OKYO Pharma prices public offering at $1.85/share to raise up to $20M

109d ago

SEC filing OKYO Pharma Transitions ATM Equity Offering to Leerink Partners, Enhances Capital Flexibility

111d ago

SEC filing 8-K Filing

123d ago

SEC filing OKYO Announces Successful FDA Type C Meeting, Confirms Phase 2b/3 Design for Urcosimod

125d ago

News OKYO Pharma Announces Chairman and Founder Acquires Shares

169d ago

Scanner Unusual volume (z=7.0)

171d ago